Sincalide is a drug owned by Maia Pharmaceuticals Inc. It is protected by 3 US drug patents filed from 2022 to 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Apr 20, 2038. Details of Sincalide's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11737983 | Storage stable sincalide formulations |
Apr, 2038
(13 years from now) | Active |
| US11318100 | Storage stable sincalide formulations |
Apr, 2038
(13 years from now) | Active |
| US11110063 | Storage stable sincalide formulations |
Apr, 2038
(13 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Sincalide's patents.
Latest Legal Activities on Sincalide's Patents
Given below is the list of recent legal activities going on the following patents of Sincalide.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Email Notification Critical | 29 Aug, 2023 | US11737983 |
| Patent eGrant Notification | 29 Aug, 2023 | US11737983 |
| Recordation of Patent eGrant | 29 Aug, 2023 | US11737983 |
| Patent Issue Date Used in PTA Calculation Critical | 29 Aug, 2023 | US11737983 |
| Mail Patent eGrant Notification | 29 Aug, 2023 | US11737983 |
| Recordation of Patent Grant Mailed Critical | 29 Aug, 2023 | US11737983 |
| Electronic Review Critical | 10 Aug, 2023 | US11737983 |
| Email Notification Critical | 10 Aug, 2023 | US11737983 |
| Issue Notification Mailed Critical | 09 Aug, 2023 | US11737983 |
| Application Is Considered Ready for Issue Critical | 14 Jul, 2023 | US11737983 |
US patents provide insights into the exclusivity only within the United States, but Sincalide is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Sincalide's family patents as well as insights into ongoing legal events on those patents.
Sincalide's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Sincalide's generic launch date based on the expiry of its last outstanding patent is estimated to be Apr 20, 2038 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Sincalide Generics:
There are no approved generic versions for Sincalide as of now.
Alternative Brands for Sincalide
Sincalide which is used for diagnosing gall bladder disorders and accelerating intestinal transit for diagnostic imaging., has several other brand drugs using the same active ingredient (Sincalide). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Bracco |
|
About Sincalide
Sincalide is a drug owned by Maia Pharmaceuticals Inc. It is used for diagnosing gall bladder disorders and accelerating intestinal transit for diagnostic imaging. Sincalide uses Sincalide as an active ingredient. Sincalide was launched by Maia Pharms Inc in 2022.
Approval Date:
Sincalide was approved by FDA for market use on 22 November, 2022.
Active Ingredient:
Sincalide uses Sincalide as the active ingredient. Check out other Drugs and Companies using Sincalide ingredient
Treatment:
Sincalide is used for diagnosing gall bladder disorders and accelerating intestinal transit for diagnostic imaging.
Dosage:
Sincalide is available in powder form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.005MG/VIAL | POWDER | Prescription | INTRAVENOUS |